全髋与全膝关节置换术中肝素与术后血栓并发症的关联:一项回顾性分析
该回顾性队列研究纳入2017至2024年单中心3132例全髋和3407例全膝置换患者,经倾向评分匹配多因素逻辑回归分析发现,术中静脉肝素与90天血栓并发症无关联(全髋OR 1.873,95%CI 0.604-5.812,P=0.277;全膝OR 0.775,95%CI 0.357-1.684,P=0.520)。无肝素组术中失血量更大,全膝组输血单位更多。作者认为该研究不支持初次全关节置换常规使用术中静脉肝素。
要点
- 术中静脉肝素与全髋置换90天血栓并发症无关联(OR 1.873,95%CI 0.604-5.812,P=0.277)。
- 术中静脉肝素与全膝置换90天血栓并发症无关联(OR 0.775,95%CI 0.357-1.684,P=0.520)。
- 无肝素组术中失血量在两组队列均更大,全膝组无肝素患者输注浓缩红细胞单位更多。
核心结论
- 术中静脉肝素与血栓并发症减少无关,本研究不支持在初次全关节置换中常规使用。
研究设计与样本
- 回顾性队列研究,纳入2017至2024年单中心行初次全髋和全膝置换的患者,共3132例全髋和3407例全膝患者。
主要发现
- 倾向评分匹配后,全髋肝素组921例中9例(1%)、无肝素组900例中5例(0.6%)发生血栓事件;全膝肝素组1397例中14例(1%)、无肝素组1319例中15例(1%)发生血栓事件。
- 全髋90天血栓并发症:肝素 vs 无肝素 OR 1.873(95%CI 0.604-5.812,P=0.277),无统计学显著关联。
- 全膝90天血栓并发症:肝素 vs 无肝素 OR 0.775(95%CI 0.357-1.684,P=0.520),无统计学显著关联。
- 无肝素组术中失血量在全髋和全膝队列均大于肝素组;全膝队列无肝素组输注浓缩红细胞单位多于肝素组,全髋队列两组无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombotic complications cause morbidity after total joint arthroplasty (TJA). Historically, some surgeons used intraoperative intravenous heparin to reduce thrombosis, but the evidence is outdated. We hypothesized that in modern TJA, intravenous heparin would not be associated with fewer thrombotic complications. METHODS: Patients who underwent primary total hip and total knee arthroplasty (THA and TKA, respectively) at a single center from 2017 to 2024 were included in this retrospective cohort study. The primary outcome was composite thrombotic complications at 90 days, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and cerebrovascular accident. The secondary outcomes included 30-day complications, intraoperative blood losses, and red blood cell transfusions. The outcome was analyzed with propensity score-matched multivariable logistic regressions based on intravenous heparin administration as a binary variable. The model was controlled for clinically relevant covariates. A total of 3,132 THA and 3,407 TKA patients were identified. After propensity score matching, we identified nine of 921 heparin (1%) and five of 900 (0.6%) no-heparin THA patients and 14 of 1,397 heparin (1%) and 15 of 1,319 (1%) no-heparin TKA patients who experienced a thrombotic event. RESULTS: There was no association between heparin and 90-day thrombotic complications for THA (odds ratio 1.873; 95% confidence interval, 0.604 to 5.812; P = 0.277) or TKA (odds ratio 0.775; 95% confidence interval, 0.357 to 1.684; P = 0.520). Intraoperative blood losses were greater in the no-heparin groups for both THA and TKA cohorts; patients in the no-heparin group in the TKA cohort received more transfused units of packed red blood cells than those in the heparin group, but there was no difference between groups in the THA cohort. CONCLUSIONS: Intraoperative intravenous heparin was not associated with a reduction in thrombotic complications, and its routine use in primary TJA is not supported by this study.
引用
- Schwenk ES, Torjman MC, Kothari R, et al. The Association Between Intraoperative Heparin and Postoperative Thrombotic Complications after Total Hip and Knee Arthroplasty: A Retrospective Analysis. J Arthroplasty. 2025. PMID: 40935347. doi:10.1016/j.arth.2025.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。